Physician profile
David M Life
NPI 1467416875
$3,840.64
in general payments reported to CMS, 2019-2025
30 companies · $420 in 2025
The $420 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $718 · 2020: $313 · 2021: $164 · 2022: $632 · 2023: $839 · 2024: $753 · 2025: $420.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,013.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,012.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $812.00 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $550.93 | 2021-2025 | |
| Glaxosmithkline, LLC. | $392.33 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Amgen INC. | $354.25 | 2019-2024 | Otezla, Repatha |
| Abbott Laboratories | $261.33 | 2021-2025 | Freestyle Libre 3 |
| Astrazeneca Pharmaceuticals LP | $224.10 | 2019-2024 | Farxiga |
| Lilly USA, LLC | $134.43 | 2022-2025 | Mounjaro, Jardiance, Trulicity |
| Amarin Pharma, INC. | $112.73 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $110.04 | 2019-2023 | Verquvo, Belsomra |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $102.09 | 2019-2023 | Xifaxan |
| Boehringer Ingelheim Pharmaceuticals, INC. | $80.20 | 2019-2024 | Jardiance |
| Mylan Specialty L.P. | $75.38 | 2023-2024 | Yupelri |
| Pfizer INC. | $74.89 | 2019-2023 | |
| Astellas Pharma US INC | $57.67 | 2022-2023 | Veozah |
| Sumitomo Pharma America, INC. | $56.18 | 2023-2024 | Gemtesa |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $47.73 | 2019-2022 | |
| Boston Scientific Corporation | $44.24 | 2023 | Wavewriter Alpha Prime 16 |
| Janssen Pharmaceuticals, INC | $40.24 | 2019-2020 | |
| Otsuka America Pharmaceutical, INC. | $39.39 | 2022-2023 | Rexulti |
| Exact Sciences Corporation | $35.59 | 2024-2025 | Cologuard Collection Kit |
| Bayer Healthcare Pharmaceuticals INC. | $35.47 | 2025 | |
| Phathom Pharmaceuticals, INC. | $29.78 | 2024 | Voquezna |
| Dexcom, INC. | $29.40 | 2021-2025 | Dexcom G6 Transmitter |
| Sanofi-Aventis U.S. LLC | $29.07 | 2022 | |
| Allergan, INC. | $26.63 | 2020 | |
| Indivior INC. | $24.75 | 2019 | |
| Xeris Pharmaceuticals, INC. | $20.28 | 2023 | Gvoke Hypopen |
| Idorsia Pharmaceuticals US INC | $14.68 | 2023 | Quviviq |
| Genentech USA, INC. | $12.42 | 2020 | |
| Eisai INC. | $12.42 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Life listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.